INVO Bioscience to Participate in the Lytham Partners Spring 2022 Investor Conference

Rhea-AI Summary

INVO Bioscience, a fertility company listed on NASDAQ under the symbol INVO, will participate in the Lytham Partners Spring 2022 Investor Conference from April 4-7, 2022. The event will feature a webcast presentation available at 11:00am ET on April 4, with replays accessible afterward. The company focuses on affordable fertility care through its innovative INVOcell® medical device and intravaginal culture (IVC) procedure, aiming to enhance accessibility to assisted reproductive technologies globally. Interested parties can arrange meetings with management through Lytham Partners.

SARASOTA, Fla., April 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

The Company's webcast presentation will be available for viewing at 11:00am ET on Monday, April 4, 2022, on the Company's website or at https://wsw.com/webcast/lytham4/invo/2054868. The webcast will also be archived and available for replay.

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at www.lythampartners.com/spring2022invreg.

About INVO Bioscience

We are a commercial-stage fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility care accessible and inclusive to people around the world. Our flagship product is INVOcell®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as "IVC", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. The IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertilization ("IVF") and is a significantly more effective treatment than intrauterine insemination ("IUI"). Our commercialization strategy is focused on the opening of dedicated "INVO Centers" offering the INVOcell® and IVC procedure (with three centers in North America now operational), in addition to continuing to sell our technology solution into existing fertility clinics. For more information, please visit www.invobio.com.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov . We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-to-participate-in-the-lytham-partners-spring-2022-investor-conference-301516403.html

SOURCE INVO Bioscience, Inc.

FAQ

What is the significance of INVO Bioscience's participation in the Lytham Partners Spring 2022 Investor Conference?

INVO Bioscience's participation highlights its commitment to expanding its presence in the fertility sector and showcases its innovative technologies to potential investors.

When will INVO Bioscience present at the Lytham Partners Spring 2022 Investor Conference?

INVO Bioscience will present at 11:00am ET on April 4, 2022.

How can investors access INVO Bioscience's presentation during the conference?

The presentation will be available via webcast on the company's website and can be replayed afterward.

What is INVOcell® and its role in fertility treatments?

INVOcell® is a medical device that enables in vivo fertilization and early embryo development, offering a more affordable and natural alternative to traditional IVF.

How does the IVC procedure compare to traditional IVF and IUI?

The IVC procedure provides comparable results to IVF at a fraction of the cost and is more effective than intrauterine insemination (IUI).

Where can I find more information about INVO Bioscience?

For more information, visit INVO Bioscience's website at www.invobio.com.